Dovitinib (CHIR258 or TKI258) is an oral ATP-competitive multikinase inhibitor that targets FGFRs, VEGFRs, and PDGFRβ.709 TKI258 has a promising inhibitory activity in cell lines with FGFR translocations or amplification.710 In phase II trials, TKI258 can stabilize disease in multiple myeloma bearing t (4;14) translocation by blocking FGFR3 activity.711. This evidence concerns the gene FGFR3 and plasma cell myeloma.